Congratulations to Cure HHT, a Patient Advocacy Group partner of the Brain Vascular Malformation Consortium (BVMC), on receiving the inaugural Prix Galien Patient First Award in Honor of Michael J. Fox in the Patient-Led Initiatives category.
The award recognizes Cure HHT’s commitment to putting patients and families at the center of progress in hereditary hemorrhagic telangiectasia (HHT). Through partnerships among patients, researchers, clinicians, advocates, and industry, Cure HHT has helped ensure that the experiences of people living with HHT inform research priorities and efforts to improve treatment and care. BVMC is proud to work alongside Cure HHT and congratulates the entire HHT community on this well\-deserved recognition.
Read the full article: Cure HHT Wins Inaugural Prix Galien Patient First Award in Honor of Michael J. Fox